William Blair Reiterates “Outperform” Rating for Exagen (NASDAQ:XGN)

Exagen (NASDAQ:XGN)‘s stock had its “outperform” rating restated by research analysts at William Blair in a research report issued to clients and investors on Wednesday,RTT News reports.

Exagen Trading Up 5.5 %

Shares of NASDAQ XGN opened at $2.90 on Wednesday. Exagen has a 1-year low of $1.30 and a 1-year high of $3.71. The company has a debt-to-equity ratio of 1.13, a current ratio of 4.32 and a quick ratio of 4.32. The business’s 50 day moving average is $2.83 and its two-hundred day moving average is $2.37. The stock has a market capitalization of $50.43 million, a P/E ratio of -2.93 and a beta of 1.35.

Exagen (NASDAQ:XGN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. Exagen had a negative net margin of 30.36% and a negative return on equity of 84.26%. The business had revenue of $12.51 million for the quarter, compared to analysts’ expectations of $13.55 million. During the same quarter in the previous year, the business posted ($0.31) earnings per share. As a group, research analysts expect that Exagen will post -1.02 EPS for the current year.

Institutional Trading of Exagen

Large investors have recently modified their holdings of the company. Verus Capital Partners LLC purchased a new stake in Exagen in the third quarter worth about $39,000. Creative Planning purchased a new position in Exagen during the 3rd quarter valued at about $110,000. Renaissance Technologies LLC raised its holdings in shares of Exagen by 93.3% in the 2nd quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock valued at $172,000 after purchasing an additional 45,476 shares in the last quarter. Palumbo Wealth Management LLC lifted its position in shares of Exagen by 14.5% in the 3rd quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company’s stock worth $236,000 after purchasing an additional 9,695 shares during the period. Finally, Stonepine Capital Management LLC boosted its stake in shares of Exagen by 49.0% during the third quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock valued at $1,651,000 after purchasing an additional 175,701 shares in the last quarter. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).